BIOTECH Logo

BIOTECH

A biotechnology group offering preclinical services, intein development, and licensing.

BST | BME Growth

Overview

Corporate Details

ISIN(s):
ES0184980003 (+1 more)
LEI:
959800GNYT6ZZEWPEW29
Country:
Spain
Address:
AVDA. DEL DESARROLLO TECNOLOGICO (PARQUE CIENTIFICO TECNOLOGICO AGROINDUSTRIAL) 11, 11591 Jerez de la Frontera

Description

Biotechnology Assets Biat Group is a biotechnology corporate group with a global commercial structure operating through several subsidiaries. Its subsidiary Biobide is a provider of preclinical services, specializing in tailor-made toxicity and efficacy testing using the zebrafish (ZF) animal model. ZIP Solutions develops and promotes a proprietary set of inteins for high-value industrial applications, including gene therapy, immunotherapy, in-vitro diagnostics, smart vaccines (RNA & DNA), and affinity-based protein purification. The Bionatur division manages biotech assets for human and animal health. The group focuses on licensing its platforms and products, conducting preclinical research, and improving recombinant and DNA vaccines through collaborations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-10-06 09:27
Net Asset Value(s)
English 4.0 KB
2021-10-05 10:09
Net Asset Value(s)
English 4.0 KB
2021-10-04 11:24
Net Asset Value(s)
English 4.0 KB
2021-10-01 12:35
Net Asset Value(s)
English 4.0 KB
2021-09-30 08:43
Net Asset Value(s)
English 4.0 KB
2021-09-29 08:18
Net Asset Value(s)
English 4.1 KB
2021-09-28 08:11
Net Asset Value(s)
English 4.1 KB
2021-09-27 09:06
Net Asset Value(s)
English 4.0 KB
2021-09-24 09:05
Net Asset Value(s)
English 4.0 KB
2021-09-23 14:24
Net Asset Value(s)
English 4.0 KB
2021-09-22 11:59
Net Asset Value(s)
English 4.0 KB
2021-09-21 09:06
Net Asset Value(s)
English 4.0 KB
2021-09-20 10:21
Net Asset Value(s)
English 4.0 KB
2021-09-17 08:47
Net Asset Value(s)
English 4.0 KB
2021-09-16 10:00
Net Asset Value(s)
English 4.0 KB

Automate Your Workflow. Get a real-time feed of all BIOTECH filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BIOTECH

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BIOTECH via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LYSOGENE Logo
A former clinical-stage biotech that developed gene therapies for rare CNS diseases.
France
LYS
MaaT Pharma Logo
A clinical-stage biotech developing microbiome-based therapeutics for oncology.
France
MAAT
Matinas BioPharma Holdings, Inc. Logo
Biopharma firm developing therapeutics using its Lipid Nanocrystal (LNC) platform.
United States of America
MTNB
Matricelf Ltd. Logo
Develops autologous, patient-specific tissue implants for regenerative medicine.
Israel
MTLF
MAXCYTE, INC. Logo
A cell-engineering company with a platform for developing cell-based therapeutics.
United States of America
MXCT
Medicofarma Biotech Spolka Akcyjna Logo
R&D company developing innovative medicines, medical devices, and biotech products.
Poland
MDB
Medigene AG Logo
Develops TCR-guided immunotherapies for cancer; currently in insolvency proceedings.
Germany
MDG1
Medizen Humancare Inc Co., Ltd Logo
A research company specializing in genomic analysis for personalized healthcare.
South Korea
236340
Medpace Holdings, Inc. Logo
A global CRO providing Phase I-IV clinical development for biotech and pharma industries.
United States of America
MEDP
A clinical-stage biotech developing nanomedicines for oncology and diagnostics.
Malaysia
N/A

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.